| abstract |
Novel baricitinib, {1-(ethylsulphonyl)-3-[4-(7 H -pyrrolo[2,3- d ]pirimidin-4-yl)- 1 H -pyrazol-1- yl]azetidin-3-yl}acetonitrile salts are disclosed, that are suitable for use as pharmaceutical active substances. More specifically, salts of baricitinib formed with ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, hydrochloric acid, 4-toluenesulfonic acid, oxalic acid, 2-hydroxyethane sulfonic acid, fumaric acid, tartaric acid and cyclamic acid are disclosed. |